By December 5th, 2015, the Translational Andrology and Urology (TAU) has passed all the evaluation required by PubMed Centre (PMC) and is officially accepted for inclusion in PubMed/PMC - an extensive and important biomedical online journal repository. All previously published content on TAU will be searchable within 1-2 months. Consequently, authors publishing in TAU will enjoy maximum exposure of their research. Acceptance in this prominent database speaks highly to the quality of the published work and the journal’s significant potential. TAU would like to express sincere appreciation for the enthusiastic and vigorous support and contributions from all board members, guest editors, reviewers, authors, and readers.
Launched in March 2012, Translational Andrology and Urology (www. amepc.org/tau) is a peer-reviewed, open-access international journal dedicating to the fields of translational andrology and urology. It was quarterly published from 2012 to 2014 and has been bi-monthly published since 2015.
Twenty-one issues have been published from March 2012 to December 2015. Among them, 3 are supplement issues and 11 are focused issues concentrating on hot topics. These Focused Issues were guest-edited by leading experts in the field (Table 1). Considering that Focused Issues would benefit readers more intensively, TAU is planning to publish more in the future (Table 2)
The journal aims to become a forum for basic researchers and clinicians to share research findings and clinical solutions, to identify new translational enterprises, and to shape future directions for basic research and clinical practice in the field. In other words, the goal of TAU is to engage the public and facilitate translation of outstanding basic science and clinical research into excellent patient care in urology and andrology.
TAU has also been indexed in Scopus and endorsed by the Genitourinary Medical Association of China International Exchange and Promotive Association for Medical and Health Care (GUA-CPAM).
TAU’s Publisher: AME Publishing Company
AME Publishing Company (www.amepc.org) is an international publisher of medical books and journals, who now owns more than 20 journals covering different fields of Medicine including oncology, pulmonology, cardiothoracic disease and urology. Each journal features peer-reviewed original contributions, comprehensive reviews, and editorials, as well as current case reports etc. AME Publishing Company have an integrated publishing system featuring a professional and highly efficient editorial team, to ensure that every part of our work from sending invitation to online publication goes as close-knit as following the assemble line, needless to say the robust electronic dissemination system for all our journals and articles. Currently, AME has 15 sister journals indexed by PubMed [PubMed Central (PMC) or MEDLINE]. Seven journals indexed in Web of Science (SCIE or ESCI): specifically, 3 journals indexed by SCIE: Journal of Thoracic Disease, Chinese Journal of Cancer Research, and Translational Cancer Research; 4 journals indexed by ESCI(Emerging Sources Citation Index)/WOS: Annals of Cardiothoracic Surgery, Journal of Gastrointestinal Oncology, Cardiovascular Diagnosis and Therapy, and Translational Gastrointestinal Cancer.
(Eunice X. Xu, Corresponding Editor, Editorial Office, Translational Andrology and Urology)